GlassScriptPhysician profile
Virginia T Sullivan
NPI 1558327098
$3,426.40
in general payments reported to CMS, 2019-2025
24 companies · $785 in 2025
The $785 reported for 2025 was more than what 81% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $900 · 2023: $929 · 2024: $407 · 2025: $785.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,121.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $490.82 | 2022-2025 | Micra, Cobalt Dr Mri Surescan, Aurora Ev-Icd Mri Surescan |
| Novartis Pharmaceuticals Corporation | $325.61 | 2021-2025 | |
| Amgen INC. | $301.35 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.82 | 2021-2025 | Lifevest |
| Pfizer INC. | $253.46 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.31 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $222.00 | 2021-2025 | Verquvo |
| Atricure, INC. | $144.67 | 2023 | |
| Novo Nordisk INC | $131.29 | 2022-2023 | Rybelsus, Ozempic |
| Boston Scientific Corporation | $121.68 | 2022-2025 | Watchman Access System, General - Therapies, Watchman Flx |
| Sanofi-Aventis U.S. LLC | $121.47 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $113.83 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $101.26 | 2021-2024 | Xarelto |
| Heartflow, INC. | $90.46 | 2022-2025 | |
| Abbott Laboratories | $86.61 | 2023-2025 | Ensite Precision, Cardiomems |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $85.37 | 2023 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $80.39 | 2021-2024 | Andexxa, Brilinta |
| Ebr Systems, INC. | $59.12 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.66 | 2024-2025 | |
| Esperion Therapeutics, INC. | $32.79 | 2022 | |
| Recor Medical INC | $25.49 | 2025 | Paradise Ultrasound Renal Denervation System |
| Actelion Pharmaceuticals US, INC. | $24.98 | 2025 | Opsumit |
| Abiomed | $23.04 | 2025 | |
| Daiichi Sankyo INC. | $20.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.